TNF and polyarticular arthritis: Other independent variables, including mechanism of action (HR = 0.76; 95% CI: 0.30–1.74 for secukinumab; HR = 0.53; 95% CI 0.15–1.86 for ustekinumab; reference: anti-TNFα), age (HR = 1.00; 95% CI: 0.99–1.03), baseline DAPSA (HR = 0.98; 95% CI: 0.96–1.00), PASI (HR = 0.95; 95% CI: 0.86–1.04), HAQ (HR = 1.29; 95% CI: 0.91–1.83), BMI (HR = 1.02; 95% CI: 0.98–1.07), polyarticular arthritis (HR = 1.23; 95% CI: 0.94–1.52), and comorbidities (HR = 1.10; 95% CI: 0.92–1.31), were not associated with the outcome “multi-failure” (Table 4).